menu
    • menu
    [{"orgOrder":0,"company":"Seismic Therapeutic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"S\u20118484","moa":"IgE receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"Seismic Therapeutic","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seismic Therapeutic \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Seismic Therapeutic \/ Undisclosed"},{"orgOrder":0,"company":"Seismic Therapeutic","sponsor":"Avance Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"S-1117","moa":"IgG","graph1":"Undisclosed","graph2":"Phase I","graph3":"Seismic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seismic Therapeutic \/ Avance Clinical","highestDevelopmentStatusID":"6","companyTruncated":"Seismic Therapeutic \/ Avance Clinical"},{"orgOrder":0,"company":"Seismic Therapeutic","sponsor":"Bessemer Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Series B Financing","leadProduct":"S-1117","moa":"IgG","graph1":"Neurology","graph2":"IND Enabling","graph3":"Seismic Therapeutic","amount2":0.02,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Seismic Therapeutic \/ Bessemer Venture Partners","highestDevelopmentStatusID":"5","companyTruncated":"Seismic Therapeutic \/ Bessemer Venture Partners"},{"orgOrder":0,"company":"Seismic Therapeutic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"S-1117","moa":"IgG","graph1":"Immunology","graph2":"Preclinical","graph3":"Seismic Therapeutic","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seismic Therapeutic \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Seismic Therapeutic \/ Undisclosed"},{"orgOrder":0,"company":"Seismic Therapeutic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"S\u20111117","moa":"IgG","graph1":"Immunology","graph2":"Phase I","graph3":"Seismic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Seismic Therapeutic \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Seismic Therapeutic \/ Undisclosed"},{"orgOrder":0,"company":"Seismic Therapeutic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"S-4321","moa":"PD?1\/c?RIIb","graph1":"Immunology","graph2":"Phase I","graph3":"Seismic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Seismic Therapeutic \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Seismic Therapeutic \/ Undisclosed"},{"orgOrder":0,"company":"Seismic Therapeutic","sponsor":"Avance Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"S-4321","moa":"PD?1\/c?RIIb","graph1":"Undisclosed","graph2":"Phase I","graph3":"Seismic Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seismic Therapeutic \/ Avance Clinical","highestDevelopmentStatusID":"6","companyTruncated":"Seismic Therapeutic \/ Avance Clinical"},{"orgOrder":0,"company":"Seismic Therapeutic","sponsor":"Lightspeed Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Seismic Therapeutic","amount2":0.10000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Seismic Therapeutic \/ Lightspeed Venture Partners","highestDevelopmentStatusID":"3","companyTruncated":"Seismic Therapeutic \/ Lightspeed Venture Partners"}]

    Find Clinical Drug Pipeline Developments & Deals by Seismic Therapeutic

    Menu

    Seismic Therapeutic

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Seismic Therapeutic

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Seismic Therapeutic

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : S-4321

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Seismic Doses First Patients with S-4321 PD-1/FcγRIIb Autoimmune Drug

                            Details : S-4321 is a novel bifunctional antibody that agonizes PD-1 and FcγRIIb inhibitory receptors for the treatment of autoimmune disease.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            April 10, 2025

                            Lead Product(s) : S-4321

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Seismic Therapeutic

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Seismic Therapeutic

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : S-4321

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Avance Clinical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 1 Study of S-4321

                            Details : S-4321 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            March 14, 2025

                            Lead Product(s) : S-4321

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Avance Clinical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Seismic Therapeutic

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Seismic Therapeutic

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : S‑1117

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Seismic Doses First Cohort in Phase 1 Trial of S-1117 for Antibody Diseases

                            Details : S‑1117 is a novel engineered Fc-fused pan-immunoglobin G (IgG) protease targeting IgG autoantibodies, which is being evaluated for the treatment of autoimmune diseases.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            March 11, 2025

                            Lead Product(s) : S‑1117

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Seismic Therapeutic

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Seismic Therapeutic

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : S‑8484

                            Therapeutic Area : Immunology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Seismic Presents Preclinical Data on S-8484 IgE Protease for Allergic Diseases

                            Details : S‑8484 is an engineered IgE protease works by rapid and sustained degradation of IgE in plasma and on IgE B cell receptors. It is being investigated for allergic disease.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            February 28, 2025

                            Lead Product(s) : S‑8484

                            Therapeutic Area : Immunology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Seismic Therapeutic

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Seismic Therapeutic

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : S-1117

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Avance Clinical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 1 Study of S-1117

                            Details : S-1117 is a Enzyme drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            February 14, 2025

                            Lead Product(s) : S-1117

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Avance Clinical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Seismic Therapeutic

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Seismic Therapeutic

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : S-1117

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Seismic Therapeutic Highlights IMPACT Platform for Creating Biologic Medicines

                            Details : The IMPACT platform was leveraged to design S-1117, a novel engineered pan-IgG protease suitable for the treatment of acute and chronic autoantibody mediated diseases.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            November 06, 2024

                            Lead Product(s) : S-1117

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Seismic Therapeutic

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Seismic Therapeutic

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : S-1117

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Bessemer Venture Partners

                            Deal Size : $21.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Seismic Therapeutic Closes $121 Million Series B Financing to Advance Immunology Pipeline Optimized by its Mac...

                            Details : The net proceeds will be used to advance through Phase 1 proof-of-mechanism trials with Seismic’s two lead programs, a pan‑immunoglobulin G protease sculpting enzyme candidate, S-1117 and a PD-1 agonist:Fc gamma receptor IIb selective DcB antibody ca...

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Undisclosed

                            December 04, 2023

                            Lead Product(s) : S-1117

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Bessemer Venture Partners

                            Deal Size : $21.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Seismic Therapeutic

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Seismic Therapeutic

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Discovery Platform

                            Sponsor : Lightspeed Venture Partners

                            Deal Size : $101.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Seismic Therapeutic Launches with $101 Million Series A Financing to Usher in a New Era of Immunology Drug Dev...

                            Details : The Series A financing will support Seismic Therapeutic’s further advancement toward the clinic of its first two lead drug programs, one targeting Ig (immunoglobulin)-mediated autoimmunity and the other targeting cell-mediated autoimmunity.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            February 09, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Discovery Platform

                            Sponsor : Lightspeed Venture Partners

                            Deal Size : $101.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth